The Global Fund's resource allocation decisions for HIV programmes: addressing those in need

BackgroundBetween 2002 and 2010, the Global Fund to Fight AIDS, Tuberculosis and Malaria's investment in HIV increased substantially to reach US$12 billion. We assessed how the Global Fund's investments in HIV programmes were targeted to key populations in relation to disease burden and national income.MethodsWe conducted an assessment of the funding approved by the Global Fund Board for HIV programmes in Rounds 1-10 (2002-2010) in 145 countries. We used the UNAIDS National AIDS Spending Assessment framework to analyze the Global Fund investments in HIV programmes by HIV spending category and type of epidemic. We examined funding per capita and its likely predictors (HIV adult prevalence, HIV prevalence in most-at-risk populations and gross national income per capita) using stepwise backward regression analysis.ResultsAbout 52% ($6.1 billion) of the cumulative Global Fund HIV funding was targeted to low- and low-middle-income countries. Around 56% of the total ($6.6 billion) was channelled to countries in sub-Saharan Africa. The majority of funds were for HIV treatment (36%; $4.3 billion) and prevention (29%; $3.5 billion), followed by health systems and community systems strengthening and programme management (22%; $2.6 billion), enabling environment (7%; $0.9 billion) and other activities. The Global Fund investment by country was positively correlated with national adult HIV prevalence. About 10% ($0.4 billion) of the cumulative HIV resources for prevention targeted most-at-risk populations.ConclusionsThere has been a sustained scale up of the Global Fund's HIV support. Funding has targeted the countries and populations with higher HIV burden and lower income. Prevention in most-at-risk populations is not adequately prioritized in most of the recipient countries. The Global Fund Board has recently modified eligibility and prioritization criteria to better target most-at-risk populations in Round 10 and beyond. More guidance is being provided for Round 11 to strategically focus demand for Global Fund financing in the present resource-constrained environment.

[1]  M. Claeson,et al.  The millennium development goals for health - rising to the challenges , 2004 .

[2]  H. Gayle,et al.  The time has come for common ground on preventing sexual transmission of HIV , 2004, The Lancet.

[3]  J. Lazarus,et al.  Know your epidemic, know your response: targeting HIV in Asia , 2010, AIDS.

[4]  Rice Dp Cost of illness studies: what is good about them? , 2000 .

[5]  B. T. Johnson,et al.  Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. , 1999, American journal of public health.

[6]  Matthew G Law,et al.  Relation between HIV viral load and infectiousness: a model-based analysis , 2008, The Lancet.

[7]  R. Walensky,et al.  Routine Voluntary HIV Testing in Durban, South Africa: The Experience From an Outpatient Department , 2007, Journal of acquired immune deficiency syndromes.

[8]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[9]  David P. Wilson,et al.  Kenya - HIV prevention response and modes of transmission analysis , 2009 .

[10]  David Wilson,et al.  HIV EPIDEMIOLOGY : A REVIEW OF RECENT TRENDS AND LESSONS , 2007 .

[11]  A. Heshmati Regional Income Inequality in Selected Large Countries , 2004, SSRN Electronic Journal.

[12]  B. Hofman,et al.  Ensuring Inter-regional Equity and Poverty Reduction , 2007 .

[13]  G. Schmid,et al.  HIV Voluntary Counseling and Testing and Behavioral Risk Reduction in Developing Countries: A Meta-analysis, 1990–2005 , 2008, AIDS and Behavior.

[14]  M. Drummond,et al.  Cost-of-illness studies: a major headache? , 1992, PharmacoEconomics.

[15]  S. Kalichman,et al.  Alcohol: the forgotten drug in HIV/AIDS , 2010, The Lancet.

[16]  R. Wanyenze,et al.  The costs and effectiveness of four HIV counseling and testing strategies in Uganda , 2009, AIDS.

[17]  Daniel Hoornweg,et al.  World bank , 2010, The SAGE Encyclopedia of Higher Education.

[18]  R. Walensky,et al.  HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies , 2009, Journal of acquired immune deficiency syndromes.

[19]  A. Keidel China Regional Disparities - The Causes and Impact of Regional Inequalities in Income and Well-Being , 2007 .

[20]  G. Vinten Guide to Producing National Health Accounts, with Special Applications for Low‐income and Middle‐income Countries , 2004 .

[21]  Matthew Hickman,et al.  HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage , 2010, The Lancet.

[22]  Enos Bernasconi,et al.  PERSONNES SEROPOSITIVES NE SOUFFRANT DAUCUNE AUTRE MST ET SUIVANT UN TRAITEMENT ANTIRETROVIRAL EFFICACE NE TRANSMETTENT PAS LE HIV PAR VOIE SEXUELLE , 2008 .

[23]  C. Ávila-Figueroa,et al.  Financing the Response to HIV in Low-Income and Middle-Income Countries , 2009, Journal of acquired immune deficiency syndromes.

[24]  S. Moses,et al.  AIDS in South Asia: Understanding and Responding to a Heterogenous Epidemic , 2006 .

[25]  M. Drummond Cost-of-Illness Studies , 1992, PharmacoEconomics.

[26]  黄亚明,et al.  Journal of the International AIDS Society , 2017 .

[27]  E. Green,et al.  A framework of sexual partnerships: risks and implications for HIV prevention in Africa. , 2009, Studies in family planning.

[28]  D. Rice,et al.  Cost of illness studies: what is good about them? , 2000, Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention.

[29]  John Stover,et al.  Towards an improved investment approach for an effective response to HIV/AIDS , 2011, The Lancet.

[30]  E. Doheny United States Agency for International Development , 2011 .

[31]  N. Hearst,et al.  Condom promotion for AIDS prevention in the developing world: is it working? , 2004, Studies in family planning.